International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.
Now that it's steered its way successfully through the treacherous waters of a Phase II/III study for a new-and-improved drug for Parkinson's, Adamas Pharmaceuticals believes this is the right time to mount a $69 million IPO bid as it sets the stage for a pivotal trial.
The Sunnyvale, CA-based Parkinson's Institute and Clinical Center and pharma company Berg are partnering to identify potential biomarkers to help diagnose and treat Parkinson's disease.
In the Journal of Medicinal Chemistry, scientists report that they've found a new compound that may offer protection against Parkinson's disease.
The healthcare burdens of aging populations have traditionally been a Western problem, but rising life expectancy in emerging markets has caused the pressures to spread around the world. In India, the co-founder of IT services firm Infosys has responded by funding a brain and computing research center to improve the health of the 100 million citizens aged over 60.
Biogen Idec is sticking close to its research home in Cambridge, MA, in its latest neurodegenerative drug development pact. The big biotech is teaming up with the neighboring Proteostasis Therapeutics on a potential new approach for attacking toxic proteins implicated in the development of Alzheimer's and Parkinson's diseases.
Using RNA interference technology, scientists have discovered a network of genes that could serve as new therapeutic targets for Parkinson's disease as well as other diseases characterized by mitochondrial damage.
Researchers have identified two different forms of Parkinson's disease--one that is more toxic than the other--which may explain why symptoms of the neurodegenerative disorder vary so greatly from one patient to another.
In what could be a breakthrough for Alzheimer's and Parkinson's research, U.K. scientists have prevented neurodegeneration in mice using an existing compound to block a pathway associated with brain cell death.
Civitas Therapeutics has scored fresh financing en route to potential late-stage development of an inhaled form of levodopa to treat symptoms of Parkinson's disease. Bay City Capital led the $38 million Series B round, which follows the start of a Phase IIb study for the startup's Parkinson's candidate CVT-301.